Detection and treatment of conditions related to luteinizing hormone/follicle-stimulating hormone (LH/FSH) levels
AssigneesUniversity of North Texas Health Science Center at Fort Worth, The Board of Regents of the University of Oklahoma
InventorDimitrios Karamichos
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for detecting or predicting a disease or condition related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) by obtaining or having obtained a biological sample from a subject; and determining the LH/FSH ratio in the biological sample, wherein a decrease in the LH/FSH ratio when compared to an age-matched subject that does not have a disease or condition of LH/FSH is indicative of a current or future disease or condition of LH/FSH.
Claims18
A method for treating a disease or condition of the eye related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) comprising:
- obtaining or having obtained a biological sample from a subject;
- determining the LH/FSH ratio in the biological sample, wherein a decrease in the LH/FSH ratio when compared to an age-matched subject that does not have a disease or condition of the eye related to an LH/FSH ratio is indicative of a current or future disease or condition of the eye related to an LH/FSH ratio in the subject;
- and administering to the subject with a decrease in the LH/FSH ratio an effective amount of gonadotropes, pituitary hormones, Gonadotropin-releasing hormones, LH, FSH, dehydroepiandrosterone sulfate (DHEA-S), Estrone, Estriol, or sex hormones, with a Prolactin-Inducible Protein (PIP) or a Gonadotropin-releasing hormone (GNRH) in an amount sufficient to increase the LH/FSH ratio.
A method of treating a subject that will develop a disease or condition of the eye related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) comprising:
- obtaining or having obtained a biological sample from the subject;
- determining a level of expression of LH and FSH in the biological sample;
- calculating the LH/FSH ratio in the biological sample;
- determining if there is a decrease in the LH/FSH ratio when compared to an age-matched subject that does not have a disease or condition of the eye related to an LH/FSH ratio, wherein a decrease in the LH/FSH ratio is indicative of a current or future disease or condition of the eye related to an LH/FSH ratio in need of treatment;
- and
- administering to the subject with a decrease in the LH/FSH ratio an effective amount of gonadotropes, pituitary hormones, Gonadotropin-releasing hormones, LH, FSH, dehydroepiandrosterone sulfate (DHEA-S), Estrone, Estriol, or sex hormones, with a Prolactin-Inducible Protein (PIP) or a Gonadotropin-releasing hormone (GNRH) in an amount sufficient to increase the LH/FSH ratio.
A method for treating a patient with a disease or condition of the eye related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio), the method comprising the steps of:
- performing or having performed a determination of the LH/FSH ratio in a biological sample obtained from a patient suspected of having a disease or condition of the eye related to an LH/FSH ratio;
- and
- administering to the subject with a decrease in the LH/FSH ratio as compared to an age-matched control that does not have a disease or condition of the eye related to an LH/FSH ratio, an effective amount of gonadotropes, pituitary hormones, Gonadotropin-releasing hormones, LH, FSH, dehydroepiandrosterone sulfate (DHEA-S), Estrone, Estriol, or sex hormones, with a Prolactin-Inducible Protein (PIP) or a Gonadotropin-releasing hormone (GNRH) in an amount sufficient to increase the LH/FSH ratio.
A method of treating a patient with Keratoconus comprising:
- obtaining a sample of corneal stromal cells from a patient suspected of having Keratoconus;
- determining a level of expression of luteinizing hormone receptor (LHR), follicle stimulating hormone receptor (FSHR), or both in the sample, wherein an increase in LHR, or a decrease of FHSR, or both as compared to an age matched subject that does not have keratoconus, is indicative of Keratoconus;
- and
- administering to the patient with Keratoconus a composition comprising an effective amount of gonadotropes, pituitary hormones, Gonadotropin-releasing hormones, LH, FSH, dehydroepiandrosterone sulfate (DHEA-S), Estrone, Estriol, or sex hormones, and a Prolactin-Inducible Protein (PIP) or a Gonadotropin-releasing hormone (GNRH) in an amount sufficient to increase an LH/FSH ratio in the patient.
Dependencies are inferred from the claim text.